Advertisement covers the 17th Conference on Retroviruses and Opportunistic Infections

The End of HIV Drug Development as We Know It?

A Blog Entry From CROI 2010

Feb. 18, 2010; 1:45 p.m. Pacific Time

Gerald Pierone Jr., M.D.

Gerald Pierone Jr., M.D.

While scanning the CROI 2010 abstracts during my six-hour plane ride to San Francisco, the thought occurred to me that we may be witnessing the winding down of the HIV drug development process.

Historically, CROI has been a high-profile event during which pharmaceutical companies would showcase their up-and-coming investigational antiretroviral agents. Not anymore.

At this conference, the number of clinical trials of novel antiretroviral agents could be counted on one hand: Gilead's "quad" tablet, elvucitabine, vicriviroc and the ViiV integrase inhibitor S/GSK1349572. There were a few interesting antiretroviral agents presented, but never has there been such a wide gap between the number of investigational pre-clinical antiretroviral agents and the compounds that are actually moving through clinical development.

There appear to be several reasons for this phenomenon. First and foremost, the bar for antiretroviral drug development has been raised to a very high level. Current combination therapy is not perfect, but about 80% of patients reach an undetectable viral load with minimal or manageable side effects. Furthermore, co-formulation of frontline antiretroviral therapy is becoming the standard, so a promising first-line agent without an already-established potential antiretroviral partner is at a disadvantage.

On the other end of the treatment spectrum, for an investigational agent looking for a niche among treatment-experienced patients, there is not a clear path forward to regulatory approval. For example, as Myles Helfand discussed in his blog, data presented at this meeting detailed the failure of the CCR5 inhibitor vicriviroc to outperform placebo in a salvage trial. The failure was not because of a lack of potency or side effects, but rather was related to the fact that the majority of patients in the placebo arm had more than two active agents in their optimized background regimen.

The misfortune that befell vicriviroc may have a chilling effect on future salvage trials. An ethical study design which would allow a potential salvage drug to demonstrate efficacy has yet to be articulated.

Copyright © 2010 Body Health Resources Corporation. All rights reserved.

This article was provided by TheBodyPRO. It is a part of the publication The 17th Conference on Retroviruses and Opportunistic Infections.
See Also
CROI 2010 Wrap-Up: The HIV Drug Development Pipeline
CROI 2010 Wrap-Up: The Evolution of Antiretroviral Therapy
CROI 2010 Wrap-Up: Complications of HIV and Its Treatment


Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.